Remus Pharmaceuticals Ltd (REMUS) is currently trading at 880.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Remus Pharmaceuticals Limited markets and distributes finished pharmaceutical formulations globally, operating through contract manufacturing, B2B distribution, and a growing B2C branded business supported by WHO‑GMP contract manufacturers, a Relius Bolivia subsidiary and a majority stake in Espee Global Holdings LLC to extend international distribution reach. Financial momentum accelerated in FY26: consolidated revenue reached INR 854 crore (+38% YoY), EBITDA INR 57 crore (+24% YoY) and net profit INR 46 crore (+20% YoY). H2 consolidated revenue was INR 453 crore (+30% YoY), reflecting export strength and growing institutional and distribution channel scale across markets. The company is actively reshaping its mix: B2C contribution rose from roughly 4% to 14% year‑on‑year and management targets materially higher B2C penetration (management indicated aspirations toward ~30% B2C), while consolidated margins are diluted by lower‑margin U.S. RLD distribution even as standalone finished‑formulation margins remain robust. Remus is expanding its high‑value pipeline and regulatory footprint with semaglutide filings for GLP‑1 therapy, licensing of Peg‑filgrastim/Filgrastim PFS, bioequivalence studies for Rivaroxaban and Dapagliflozin in Chile, clearance of the Peru DIGEMID audit and aggressive product filing plans (60 products planned), indicating meaningful product and market expansion. Working capital and cash conversion are a focus area: consolidated operating cash flow remains modest due to inventory held for RLD distribution in the U.S. and cyclical debtor timing, with management citing advance payment policies, planned normalization, and targeted operational improvements to improve cash conversion.

Over the past 52 weeks, Remus Pharmaceuticals Ltd has traded between a low of ₹580.00 and a high of ₹1,039.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Remus Pharmaceuticals Ltd has a market capitalization of approximately 1,037.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Remus Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,037.70 Cr, Remus Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Remus Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Remus Pharmaceuticals Ltd is 28.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.